LINC02329

Across TCGA pan-cancer cohorts, LINC02329 RNA is linked to patient survival in 6 of 34 cancer types, making it the most broadly survival-associated LINC02329 data layer.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher LINC02329 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LINC02329 expression acts as an unfavorable survival marker, although some lineages such as ESCA show a favorable association.

BRCA, STAD, and ESCA are the cancer types where LINC02329 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Tertile	All	0.621	0.926	<.001	66	view →
STAD	DFS	Tertile	All	0.429	0.669	.003	36	view →
ESCA	DFS	Tertile	II,III,IV	0.755	0.288	.028	33	view →
KIRP	OS	Tertile	All	0.642	0.951	<.001	27	view →
SKCM	DFS	Tertile	III,IV	0.063	0.616	<.001	18	view →
UCEC	OS	Tertile	All	0.782	0.928	.037	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LINC02329–BRCA (OS)

Open the BRCA breakdown →